{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T08:05:40Z","timestamp":1789373140425,"version":"build-2803163510"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.msard.2026.107675","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T06:56:42Z","timestamp":1787295402000},"page":"107675","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Longitudinal changes in serum immunoglobulin levels and peripheral immune cell counts during ocrelizumab treatment in people with multiple sclerosis"],"prefix":"10.1016","volume":"114","author":[{"given":"Maddalena","family":"Sparaco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Mele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Cimmino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Signoriello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8561-9720","authenticated-orcid":false,"given":"Simona","family":"Bonavita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107675_bib0001","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s00415-022-11350-1","article-title":"Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study","volume":"270","author":"Capasso","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2026.107675_bib0002","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5. Published: November 27,. 2017. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute."},{"key":"10.1016\/j.msard.2026.107675_bib0003","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00415-025-13133-w","article-title":"Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis","volume":"272","author":"Davies","year":"2025","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2026.107675_bib0007","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200091","article-title":"Immune profiling reveals the T-cell effect of Ocrelizumab in early relapsing-remitting multiple sclerosis","volume":"10","author":"Garcia","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.msard.2026.107675_bib0008","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1365-2249.2007.03545.x","article-title":"Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities","volume":"151","author":"Gonzalez-Quintela","year":"2007","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.msard.2026.107675_bib0009","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s40801-025-00486-x","article-title":"Long-term evaluation of effectiveness and immunological implications of Ocrelizumab in a real-world cohort","volume":"12","author":"Guerra","year":"2025","journal-title":"Drugs Real World Outcomes"},{"key":"10.1016\/j.msard.2026.107675_bib0010","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.msard.2026.107675_bib0011","doi-asserted-by":"crossref","first-page":"e1546","DOI":"10.1212\/WNL.0000000000012700","article-title":"Safety of Ocrelizumab in patients with relapsing and primary progressive multiple sclerosis","volume":"97","author":"Hauser","year":"2021","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2026.107675_bib0012","article-title":"Hypogammaglobulinemia and infection rates in patients with multiple sclerosis treated with ocrelizumab for up to six years: a real-world single-center study","volume":"11","author":"Khatri","year":"2025","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2026.107675_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105776","article-title":"Ocrelizumab in people with primary progressive multiple sclerosis: a real-world multicentric study","volume":"89","author":"Krbot Skori\u0107","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107675_bib0014","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.msard.2026.107675_bib0015","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/acn3.51732","article-title":"Real-world evaluation of ocrelizumab in multiple sclerosis: a systematic review","volume":"10","author":"Montalban","year":"2023","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"41","key":"10.1016\/j.msard.2026.107675_bib0016","doi-asserted-by":"crossref","first-page":"25690","DOI":"10.1073\/pnas.2012249117","article-title":"B cells reappear less mature and more activated after their anti-CD20\u2013mediated depletion in multiple sclerosis","volume":"117","author":"Nissimov","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.msard.2026.107675_bib0017","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jaci.2022.01.025","article-title":"Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a work group report of the AAAAI primary immunodeficiency and altered immune response committees","volume":"149","author":"Otani","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.msard.2026.107675_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104400","article-title":"Infection risk in a real-world cohort of patients treated with long-term B-cell depletion for autoimmune neurologic disease","volume":"68","author":"Peters","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107675_bib0019","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s40263-021-00810-3","article-title":"Predicting infection risk in multiple sclerosis patients treated with ocrelizumab: a retrospective cohort study","volume":"35","author":"Seery","year":"2021","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.msard.2026.107675_bib0020","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2020-000108","article-title":"Clinical outcomes of patients with multiple sclerosis treated with ocrelizumab in a US community MS center: an observational study","volume":"3","author":"Smoot","year":"2021","journal-title":"BMJ Neurol. Open"},{"issue":"2","key":"10.1016\/j.msard.2026.107675_bib0021","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826007108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826007108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T07:04:48Z","timestamp":1789369488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826007108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":18,"alternative-id":["S2211034826007108"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107675","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal changes in serum immunoglobulin levels and peripheral immune cell counts during ocrelizumab treatment in people with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107675","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107675"}}